Polymyositis complicating D-penicillamine treatment.
Although there is good evidence that D-penicillamine can induce polymyositis, the exact pathogenic mechanism remains unclear. We report two patients with psoriatic arthritis and primary biliary cirrhosis respectively, who developed polymyositis while receiving D-penicillamine treatment for their primary diseases. Whether D-penicillamine treatment was the sole cause of polymyositis or acted as a trigger for the development of a secondary autoimmune disease is discussed.
Aydintug
A O
AO
Lupus Arthritis Research Unit, Rayne Institute, St Thomas' Hospital, London, UK.
Cervera
R
R
D'Cruz
D
D
Ramírez
G
G
Asherson
R A
RA
Khamashta
M A
MA
Hughes
G R
GR
D000328:Adult; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy*; D008875:Middle Aged; D009220:Myositis / Q000139:chemically induced*; D010396:Penicillamine / Q000009:adverse effects*
D010396:Penicillamine